A detailed history of Continuum Advisory, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Continuum Advisory, LLC holds 1,289 shares of BCRX stock, worth $9,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,289
Previous 1,198 7.6%
Holding current value
$9,757
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$6.41 - $8.69 $583 - $790
91 Added 7.6%
1,289 $9,000
Q1 2024

May 10, 2024

BUY
$4.89 - $7.65 $5,858 - $9,164
1,198 New
1,198 $6,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Continuum Advisory, LLC Portfolio

Follow Continuum Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continuum Advisory, LLC with notifications on news.